Post by Tzu Cancer Therapeutics

Our CBO Mike Shaw is just back from this year’s Bio conference in San Diego.  Many thanks to all of the people who found time to discuss our therapeutic programs, and the technology Tzu Cancer Therapeutics has developed to study metastasising biology through the isolation and single cell DNA+RNA sequencing ananysis of Circulating Tumor Cells. There were some great conversations about how this technology could be used for target identification, for clinical efficacy monitoring, and to stratify clinical trials. Didn't get to meet us in San Diego? Reach out to [email protected] if you are interested to learn more about our technology and partnership opportunities!